Making Sense of the Market’s Massive Pullback, and Digging in on Ford & Chipotle Earnings 7/24/24
CNBC's "Fast Money"
00:00
Advancement of GLP1 Weight Loss Drug by Viking Therapeutics and Eli Lilly's Progress
The chapter covers Viking Therapeutics' plans to move their injectable GLP1 weight loss drug to Phase 3 and their oral GLP1 to Phase 2. Additionally, it discusses Eli Lilly's new street high price target, progress in a study, potential acquisition prospects, and the impact on stock value.
Play episode from 34:02
Transcript
